Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 2/20 | 0.35 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL935524 | 0.88 | HIF1A (0.40) | PTGS2MCL1HIF1APTGS1PPARG | |
| SCHEMBL8515249 | 0.87 | LPAR1 (0.41) | PTGS2MCL1HIF1AGCKPPARG | |
| SCHEMBL8514743 | 0.86 | MCL1 (0.43) | PTGS2MCL1HIF1APTGS1PPARG | |
| SCHEMBL8514936 | 0.84 | MCL1 (0.53) | MCL1PTGS1BCL2BCL2L2 | |
| SCHEMBL8515326 | 0.83 | MCL1 (0.45) | PTGS2MCL1HIF1A | |
| SCHEMBL8513874 | 0.82 | HIF1A (0.39) | PTGS2MCL1HIF1APPARG | |
| SCHEMBL8513539 | 0.82 | HIF1A (0.39) | PTGS2MCL1HIF1AGCKPPARG | |
| SCHEMBL955080 | 0.81 | GCK (0.46) | GCK | |
| SCHEMBL2657088 | 0.80 | MCL1 (0.36) | PTGS2MCL1HIF1AGCKPTGS1 | |
| SCHEMBL1008308 | 0.80 | MCL1 (0.36) | PTGS2MCL1HIF1AGCKPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456767-B1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | claimed |
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | claimed |
| EP-2456767-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-05-30 | — | — | EP | claimed |
| EP-2456767-B1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2456767-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | PTGS2 978/4885MCL1 4634/4885HIF1A 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.